Scientific image

Breaking New Ground in Oncology

Sanofi's Approach to Oncology R&D

Sanofi is investing substantially in the next generation of cancer medicines. With clear focus, deep internal expertise, and industry-leading partners, its scientists are set to bring new and potentially life-transforming medicines to cancer patients worldwide.

Oncology Pipeline

Building on a long tradition of world-leading oncology research, Sanofi is focused on advancing next-generation therapies in four core areas: multiple myeloma and other blood cancers, skin cancers, lung cancers, breast cancer and other hormone-positive cancers.

Antibody drug conjugates
13
MAJOR R&D TECHNOLOGY PLATFORMS, FROM MULTISPECIFICS TO NANOBODIES
11
ONCOLOGY DRUGS IN CLINICAL DEVELOPMENT
15
NEW MOLECULAR ENTITIES IN ONCOLOGY WITH FIRST-IN-CLASS OR BEST-IN-CLASS POTENTIAL

Today, Sanofi has 11 drugs in clinical development and approximately 15 additional new molecular entities in oncology with first-in-class or best-in-class potential, poised to enter clinical development in the next two to three years. We are committed to translating scientific discoveries into potential new treatments and addressing critical gaps in care across a variety of cancers.

Because tumors often mutate, simultaneous treatment with multiple therapeutics is one promising approach. Sanofi scientists are testing diverse drug combinations to invent differentiated molecules that tackle targets in immuno-oncology and molecular oncology.

DNA

Technologies

By rapidly advancing novel biologic platforms–including antibody-drug conjugates, fusion proteins, multi-specific antibodies, nanobody technology, and Synthorins®–Sanofi is laying the foundations for next-generation therapeutics with the potential to conquer some of the most difficult-to-treat cancers.

These technologies form a unique toolkit that enables the oncology R&D teams to develop novel small-molecule drugs and monoclonal antibodies that can one day offer new options for patients.

Zoom on a cancer cell

Partnerships

To further our bold vision of generating multiple candidates every year, Sanofi is leveraging a rapidly growing set of technologies that further strengthen its R&D pipeline while collaborating with innovative partners to break new ground in oncology.

With many investigational compounds currently in clinical trials, we remain focused on advancing scientific discoveries that may improve the lives of people around the world living with cancer.

People with Cancer during COVID-19

Supporting People with Cancer during COVID-19

Continuity of care is essential to ensure that people fighting cancer have the best possible chance at a positive outcome

Forging new paths in R&D for cancer treatments

Portrait of Danielle Kirzeder, a patient

Sanofi’s Commitment to Oncology

Small molecule protein degrader

Targeting estrogen receptors in breast cancer

Identifying a New Target to Address an Old Challenge: CEACAM5 and Lung Cancer

Voices from the Lab: Marie-Priscille Brun on Antibody-Drug Conjugates

Voices from the Lab: Pieter Deschaght on Nanobody® Technologies

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK